$1,060,000 of ABBOTT LABORATORIES lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"S. 1000/H.R. 1835 Saving Access to Laboratory Services Act. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Proposals related to Medicare coverage of continuous glucose monitors. Proposals to ensure Medicare coverage for emerging medical device technology. Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule. Proposals related to U.S. global health programs and pandemic preparedness. Proposals to advance global virus surveillance. Proposals regarding infant and child nutrition. Proposals related to tariffs on products imported into the United States. Proposals related to access to infant formula. Public Law 115-97 The Tax Cuts and Jobs Act. Public Law 117-169 Inflation Reduction Act of 2022. Proposals to reform domestic and international tax structures. S. 2477/H.R. 1770 Equitable Community Access to Pharmacist Services Act. Proposals related to medical device cybersecurity. Proposals related to heart valve repair technologies. Proposals related to sterilization of medical devices. Proposals related to testing for malaria. Proposals related to the President's Emergency Plan for AIDS Relief (PEPFAR)."
You can find more data on corporate lobbying on Quiver Quantitative.
ABT Congressional Stock Trading
Members of Congress have traded $ABT stock 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- SENATOR MARKWAYNE MULLIN sold up to $50,000 on 12/11.
- REPRESENTATIVE JOHN JAMES sold up to $15,000 on 09/04.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 2 times. They made 2 purchases worth up to $30,000 on 08/19, 07/29 and 0 sales.
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 07/23.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ABT Insider Trading Activity
ABT insiders have traded $ABT stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- HUBERT L ALLEN (EXECUTIVE VICE PRESIDENT) has made 0 purchases and 3 sales selling 157,421 shares for an estimated $18,424,298.
- ROBERT B FORD (CHAIRMAN AND CEO) has made 0 purchases and 2 sales selling 141,679 shares for an estimated $16,493,217.
- JOHN A. JR. MCCOY (VICE PRESIDENT) sold 27 shares for an estimated $3,100
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ABT Hedge Fund Activity
We have seen 1,204 institutional investors add shares of ABT stock to their portfolio, and 1,294 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 14,142,281 shares (+95.7%) to their portfolio in Q3 2024, for an estimated $1,612,361,456
- BANK OF AMERICA CORP /DE/ removed 7,332,824 shares (-39.1%) from their portfolio in Q3 2024, for an estimated $836,015,264
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 6,062,765 shares (-86.2%) from their portfolio in Q3 2024, for an estimated $691,215,837
- CAPITAL INTERNATIONAL INVESTORS removed 6,055,899 shares (-8.4%) from their portfolio in Q3 2024, for an estimated $690,433,044
- CAPITAL RESEARCH GLOBAL INVESTORS removed 3,935,660 shares (-6.9%) from their portfolio in Q3 2024, for an estimated $448,704,596
- BARCLAYS PLC removed 3,264,479 shares (-42.5%) from their portfolio in Q3 2024, for an estimated $372,183,250
- WINSLOW CAPITAL MANAGEMENT, LLC removed 2,894,590 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $330,012,205
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
